Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection

Journal of Infectious Diseases

Volumn 187, Issue 8, 2003, Pages 1264-1271

  Yee, Leland J ^a,b,e   Perez, Kevin A ^a,c   Tang, Jianming ^a,d   Van Leeuwen, Dirk J ^b,f   Kaslow, Richard A ^a,b,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; RIBAVIRIN;

ADULT; ARTICLE; CELL ACTIVITY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; EXON; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMOZYGOSITY; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCONJUGATES; INTERFERON-ALPHA; LINKAGE (GENETICS); MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TIME FACTORS;

EID: 0037446909     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374561     Document Type: Article

References (55)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
2. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26:112S-21S.
3. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-32.
4. McHutchison JG, Gordon SC, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
5. Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30:192-8.
6. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov N. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346-55.
7. + T-cell response in acute hepatitis C. Gastroenterology, 1999; 117:933-41.
8. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-7.
9. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706-14.
10. Cramp M, Carucci P, Rossol S, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV-positive patients without hepatitis C viraemia. Gut 1999; 44:424-9.
11. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995; 21:632-8.
12. Koziel MJ, Dudley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149:3339-44.
13. Koziel MJ, Dudley D, Afdhal N, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67:7522-32.
14. Hiroishi K, Kita H, Kojima M, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25:705-12.
15. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158:1473-81.
16. Nelson D, Marousis C, Ohno T, Davis G, Lau J. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity, and response to interferon alpha therapy in chronic hepatitis C. Hepatology 1998; 28:225-30.
17. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis C and the human genome. Hepatology 2000; 31:819-27.
18. Edwards-Smith C, Jonsson JR, Purdie D, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alpha. Hepatology 1999; 30:526-30.
19. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33:708-12.
20. Dariavach P, Mattei MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18:1901-5.
21. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human BT-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801 [erratum: Immunity 1995; 2:203].
22. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13.
23. Lindsten T, Lee KP, Harris ES, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993; 151:3489-99.
24. Kristiansen O, Larsen Z, Pociot F. CTLA-4 in autoimmune diseases: a general susceptibility gene to autoimmunity? Genes Immun 2000; 1:170-84.
25. + T cell responses. Proc Natl Acad Sci USA 1999; 96:8603-8.
26. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-65.
27. Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev 1996; 153:155-82.
28. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-8.
29. Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 1997; 94:9296-301.
30. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-7.
31. Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J. An MseI RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 1996; 225:817-8.
32. Larsen ZM, Kristiansen OP, Mato E, et al. IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent). Autoimmunity 1999; 31:35-42.
33. Nistico L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996; 5:1075-80.
34. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165:6606-11.
35. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001; 2:145-52.
36. Maurer M, Loserth S, Kolb-Maurer A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002; 54:1-8.
37. Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002; 3:233-4.
38. Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van Leeuwen DJ. Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infect Dis 2001; 1:8.
39. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor hepatitis C virus (HCV) monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol 2002; 40:768-73.
40. Hayashi J, Kishihara Y, Ueno K, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998; 158:177-81.
41. Olerup O, and Zetterquist H. HLA-DR typing by polymerase chain reaction amplification with sequence-specific primers (PCR-SSP). In: Hui KM, Bidwell JL, eds. Handbook of HLA typing techniques. Boca Raton: CRC Press, 1993:149-73.
42. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute, 1996.
43. van Endert PM, Lopez MT, Patel SD, Monaco JJ, McDevitt HO. Genomic polymorphisms, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes. Proc Natl Acad Sci USA 1992; 89:11594-7.
44. Donner H, Seidl C, Braun J, et al. CTLA4 gene haplotypes cannot protect from IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families. Diabetes 1998; 47:1158-60.
45. Missale G, Cariani E, Lamonaca V, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26:792-7.
46. Lenschow DJ, Herold KC, Rhee L, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5:285-93.
47. Kuchroo VK, Das MP, Brown IA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80:707-18.
48. + T cells. Proc Natl Acad Sci USA 2000; 97:12711-6.
49. Chang KM, Thimme R, Melpolder JJ, et al. Differential CD4 and CD8 T-cell responsiveness in hepatitis C virus infection. Hepatology 2001;33:267-76.
50. Saldanha J, Lelie N, Heath A, et al. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 1999; 76:149-58.
51. Gretch DR, dela Rosa C, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995; 123:321-9.
52. Jacob S, Baudy D, Jones E, Xu L, Mason A, Regenstein F, Perrillo RP. Comparison of quantitative HCV RNA assays in chronic hepatitis C. Am J Clin Pathol 1997; 107:362-7.
53. Lunel F, Cresta P, Vitour D, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology 1999; 29:528-35.
54. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Comparison of 3 quantitative HCV RNA assays: accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998; 30:441-6.
55. Pawlotsky J-M. Measuring hepatitis C viremia: can we trust the assays? Hepatology 1997; 26:1-4.